Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Morepen Laboratories posts Q2 FY24 consolidated PAT at Rs. 21.25 Cr

Morepen Laboratories has reported total income of Rs. 425 crores during the quarter ended September 30, 2023

Dr Lal Path Labs posts Q2 FY24 consolidated PAT at Rs. 109.3 Cr

Dr. Lal Path Labs has reported total income of Rs. 619.4 crores during the period ended September 30, 2023

Zydus acquires UK based LiqMeds Group

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026

Lupin Mandideep plant gets USFDA green signal

The inspection of the facility conducted from August 7 to August 11, 2023

Pfizer posts Q3 loss as Covid-19 revenues shrink

Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion

Aragen setting up a US$ 30 million bio-manufacturing site in Bengaluru

Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution

Indian Health Minister Dr. Mandaviya addresses 76th session of the WHO Regional Committee for South-East Asia

India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter

USFDA accepts for review AstraZeneca’s supplemental biologics license application for self-administration of FluMist Quadrivalent

The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer